Biorestorative Therapies (NASDAQ:BRTX) Trading Up 5.9% – Here’s Why

Biorestorative Therapies, Inc. (NASDAQ:BRTX)’s stock price shot up 5.9% on Tuesday . The company traded as high as $1.1654 and last traded at $1.1654. Approximately 15,115 shares changed hands during trading, a decline of 55% from the average session volume of 33,781 shares. The stock had previously closed at $1.10.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Biorestorative Therapies in a report on Monday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Biorestorative Therapies presently has an average rating of “Sell”.

Biorestorative Therapies Price Performance

The firm’s 50-day moving average price is $1.25 and its 200-day moving average price is $1.46. The company has a market cap of $10.34 million, a price-to-earnings ratio of -0.79 and a beta of 0.18.

Biorestorative Therapies (NASDAQ:BRTX) last posted its earnings results on Wednesday, November 12th. The company reported ($0.38) earnings per share for the quarter, meeting the consensus estimate of ($0.38). Biorestorative Therapies had a negative net margin of 3,308.09% and a negative return on equity of 231.08%. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.46 million. On average, sell-side analysts anticipate that Biorestorative Therapies, Inc. will post -1.43 earnings per share for the current year.

Institutional Investors Weigh In On Biorestorative Therapies

An institutional investor recently bought a new position in Biorestorative Therapies stock. Citadel Advisors LLC purchased a new stake in Biorestorative Therapies, Inc. (NASDAQ:BRTX) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 106,210 shares of the company’s stock, valued at approximately $152,000. Citadel Advisors LLC owned about 1.20% of Biorestorative Therapies as of its most recent filing with the Securities and Exchange Commission (SEC). 69.38% of the stock is currently owned by institutional investors.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.